Nebenwirkungen · Tasmar
Tasmar 100 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 9
HOS-086583 · Präparat HOS-083306
Increase of alanine aminotransferase Increases to more than three times the upper limit of normal (ULN) in alanine aminotransferase (ALT) occurred in 1 % of patients receiving Tasmar 100 mg three times daily, and 3 % of patients at 200 mg three times daily. Increases were approximately two times more likely in females. The increases usually appeared within 6 to 12 weeks of starting treatment, and were not associated with any clinical signs or symptoms. In about half the cases, transaminase levels returned spontaneously to baseline values whilst patients continued Tasmar treatment. For the remainder, when treatment was discontinued, transaminase levels returned to pre-treatment levels.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage ae486349b069d183991d7c096e0499c8e91ad01afbb5c38f2790bd21b99f77d7 · Zeichen 4688–5381 im Abschnitt